NASDAQ:MORF - Morphic Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $67.83
  • Forecasted Upside: 105.56 %
  • Number of Analysts: 7
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 7 Buy Ratings
  • 0 Strong Buy Ratings
$33.00
▲ +3.88 (13.32%)

This chart shows the closing price for MORF by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Morphic Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MORF and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MORF

Analyst Price Target is $67.83
▲ +105.56% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Morphic in the last 3 months. The average price target is $67.83, with a high forecast of $83.00 and a low forecast of $45.00. The average price target represents a 105.56% upside from the last price of $33.00.

This chart shows the closing price for MORF for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 7 polled investment analysts is to buy stock in Morphic. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/18/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/19/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/17/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/15/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/13/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/14/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/13/2022
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/12/2022

Latest Recommendations

  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/5/2022BMO Capital MarketsReiterated RatingBuy$83.00Low
8/4/2022Wells Fargo & CompanyLower Price TargetOverweight$79.00 ➝ $77.00Low
8/4/2022Royal Bank of CanadaLower Price TargetOutperform$76.00 ➝ $70.00N/A
7/20/2022SVB LeerinkInitiated CoverageOutperform$45.00Low
3/31/2022Canaccord Genuity GroupInitiated CoverageBuyLow
3/31/2022Canaccord Genuity GroupInitiated CoverageBuy$68.00Low
2/28/2022BMO Capital MarketsLower Price Target$102.00 ➝ $83.00High
2/25/2022Royal Bank of CanadaLower Price TargetOutperform$82.00 ➝ $76.00Medium
2/11/2022BTIG ResearchInitiated CoverageBuy$64.00High
12/8/2021Wells Fargo & CompanyInitiated CoverageOverweight$81.00High
5/3/2021BMO Capital MarketsLower Price TargetOutperform$111.00 ➝ $102.00High
3/1/2021Wells Fargo & CompanyBoost Price Target$40.00 ➝ $103.00High
2/2/2021Royal Bank of CanadaBoost Price TargetOutperform$35.00 ➝ $50.00Low
10/26/2020Royal Bank of CanadaInitiated CoverageOutperform$35.00High
8/26/2020BMO Capital MarketsReiterated RatingBuy$37.00Medium
8/11/2020BMO Capital MarketsBoost Price TargetOutperform$30.00 ➝ $37.00Low
7/5/2020BMO Capital MarketsReiterated RatingBuyLow
3/5/2020CowenReiterated RatingBuyLow
8/13/2019BMO Capital MarketsBoost Price TargetOutperform$30.00 ➝ $32.00High
8/12/2019CowenReiterated RatingBuyHigh
7/22/2019Jefferies Financial GroupInitiated CoverageBuy ➝ BuyHigh
7/22/2019CowenInitiated CoverageOutperform ➝ OutperformHigh
7/22/2019Wells Fargo & CompanyInitiated CoverageOutperform ➝ OutperformHigh
7/22/2019BMO Capital MarketsInitiated CoverageOutperform ➝ Outperform$30.00High
(Data available from 8/12/2017 forward)

News Sentiment Rating

0.22 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
1/14/2022
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
2/13/2022
  • 3 very positive mentions
  • 4 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
3/15/2022
  • 1 very positive mentions
  • 5 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
4/14/2022
  • 1 very positive mentions
  • 10 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
5/14/2022
  • 1 very positive mentions
  • 9 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
6/13/2022
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/13/2022
  • 3 very positive mentions
  • 18 positive mentions
  • 5 negative mentions
  • 0 very negative mentions
8/12/2022

Current Sentiment

  • 3 very positive mentions
  • 18 positive mentions
  • 5 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.
Morphic logo
Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; and preclinical trial to treat idiopathic pulmonary fibrosis and fibrosis diseases. The company is also developing avß6 for the treatment of fibrotic diseases, and avß8 to treat solid tumors, as well as various other products. Morphic Holding, Inc. has a research collaboration with Engitix Ltd for the identification of Morphic integrin technology amenable targets in fibrostenotic IBD; a collaboration agreement with Schrödinger, LLC for integrin targets; and a license agreement with Children's Medical Center Corporation to develop and commercialize products worldwide for any therapeutic or diagnostic use in humans and veterinary applications. It also has collaboration agreements with AbbVie Biotechnology Ltd and Janssen Pharmaceuticals, Inc. to discover or develop integrin-based therapeutics. Morphic Holding, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.
Read More

Today's Range

Now: $33.00
Low: $29.12
High: $33.14

50 Day Range

MA: $24.57
Low: $19.74
High: $33.37

52 Week Range

Now: $33.00
Low: $19.23
High: $68.75

Volume

325,486 shs

Average Volume

339,910 shs

Market Capitalization

$1.27 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.51

Frequently Asked Questions

What sell-side analysts currently cover shares of Morphic?

The following equities research analysts have issued research reports on Morphic in the last twelve months: BMO Capital Markets, BTIG Research, Canaccord Genuity Group Inc., Royal Bank of Canada, SVB Leerink LLC, and Wells Fargo & Company.
View the latest analyst ratings for MORF.

What is the current price target for Morphic?

6 Wall Street analysts have set twelve-month price targets for Morphic in the last year. Their average twelve-month price target is $67.83, suggesting a possible upside of 109.9%. BMO Capital Markets has the highest price target set, predicting MORF will reach $83.00 in the next twelve months. SVB Leerink LLC has the lowest price target set, forecasting a price of $45.00 for Morphic in the next year.
View the latest price targets for MORF.

What is the current consensus analyst rating for Morphic?

Morphic currently has 7 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe MORF will outperform the market and that investors should add to their positions of Morphic.
View the latest ratings for MORF.

How do I contact Morphic's investor relations team?

Morphic's physical mailing address is 35 Gatehouse Drive A2, Waltham MA, 02451. The company's listed phone number is (781) 996-0955. The official website for Morphic is www.morphictx.com. Learn More about contacing Morphic investor relations.